Good point, willing to bet LLMab won't have those

Quote:

---

Saag said a main problem hindering his use of the monoclonal antibodies is that most patients are either referred to him too late, after seven days of illness, or they don't meet criteria outlined in the FDA's emergency use authorization for the treatment: over age 65 or have significant underlying health problems.

Medicines authorized for emergency use must follow strict guidelines outlined in the EUA, as it's called, so doctors do not have the flexibility to try them in other groups.

---

Quote:

---

But many doses sit untouched at health care facilities across the country, with providers reluctant to them.

"A lot of us in infectious disease aren't sure that the monoclonal antibodies are worth the effort," said Dr. Christopher Ohl, a professor of infectious diseases at Wake Forest School of Medicine in Winston-Salem, North Carolina.

Some doctors on the front lines of treating Covid-19 patients have actually declined their allotments of the treatment, citing lack of evidence it really works.

"This is not something that's ready for prime time," said Dr. Pieter Cohen, an associate professor at Harvard Medical School and physician with the Cambridge Health Alliance Respiratory Clinic near Boston

---